Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 82   

Articles published

ARNA 3.99 -0.06 (-1.48%)
price chart
Will Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Surprise Analysts? - Investor ...
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) is next slated to report earnings for the current quarter on 2015-08-07. Brokerages covering the stock are currently expecting the firm to earn $-0.15 per share based on the 4 covering brokerages weighted into ...
Arena Pharmaceuticals (ARNA) Showing Signs Of Perilous Reversal Today
Arena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel drugs that target G protein-coupled receptors.
Arena Benefits From Celgene Buyout Of Receptos  Seeking Alpha
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Analyst Rating Update  Insider Trading Report
Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells ...
Arena Pharmaceuticals Inc.'s shares have lost 7.37% in the last one month and 6.53% in the previous three months. However, the stock has gained 19.60% on YTD basis.
Biotech Stocks To Love - Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Novavax ...
Mr. Hoffman is expected to remain in his current role at Arena until July 10, 2015. “Robert has been a valuable member of our management team and, on behalf of myself and the company, I thank him for his years of leadership and service to Arena,” said ...
Company Shares of Arena Pharmaceuticals, Inc. Drops by -0.68%
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has dropped 0.68% during the past week, however, the bigger picture is still very bullish; the shares have posted positive gains of 11.85% in the last 4 weeks.
Momentum Stock in Focus - Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)  Enterprise Leader
Healthcare Sector Movers: Halozyme Therapeutics, Inc. (HALO), Arena ...  WallStreet Scope
Analyst Price Target Update on Arena Pharmaceuticals, Inc.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA): The mean estimate for the short term price target for Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) stands at $5.63 according to 4 Analysts. The higher price target estimate for the stock has been calculated at $8 ...
Arena Pharmaceuticals Inc (NASDAQ:ARNA) in Spotlight
[EDGAR] Arena Pharmaceuticals Inc (NASDAQ:ARNA)(TREND ANALYSIS) On July 9, 2015, our Board of Directors appointed Jack Lief, our President and Chief Executive Officer, as our principal financial officer, and Jennifer K. Bielasz, our Vice President, ...
Top Biotech Stock Picking - Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX ...  Wall Street Observer
Company Shares of Arena Pharmaceuticals, Inc. Rally 4.9%
Shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) rose by 4.9% in the past week and 1.81% for the last 4 weeks. In the past week, the shares have outperformed the S&P 500 by 2.43% and the outperformance increases to 1.01% for the last 4 weeks.
Will Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Surprise This Quarter?
Most recently for the quarter ending on 2015-03-31, Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) posted a surprise factor of 28.57%.
Shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Sees Large Outflow of Money  OTC Outlook
Fall in love with these 3 Biotech stocks - Arena Pharmaceuticals, Inc. (NASDAQ ...
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) rose +7.91% to end last trading session at $4.64. The company, on June 16, 2015, released that Robert E. Hoffman, Senior Vice President, Finance and Chief Financial Officer, has decided to leave the company ...
Healthcare Sector Update: KERX, IDRA, ARNA, CLDX  Wsnews4investors (press release) (blog)